Kohei Hara/DigitalVision via Getty ImagesSince my last article, Johnson & Johnson's stock price (NYSE:JNJ) has been trading sideways until July 10, mainly due to caution from financial market participants about the impact of the talcum-powder litigation on its financial position. On the other hand, the company reported Q2 2024 financial results on July 17 that beat my expectations as well as Wall Street's. It also pleased investors with the progress in developing its portfolio of FDA-approved medicines  ...